Historically, HR+ breast cancer has been classified as immunologically ‘cold’ due to low programmed cell death ligand 1 (PD-L1) expression, fewer tumor-infiltrating lymphocytes (TILs), and low median tumor mutational burden (TMB), leading to a limited response to immune checkpoint inhibitors (ICIs) [3,4,5]. Here, CD274 is linked to breast carcinoma.